Listas Anotadas de Medicamentos e Dispositivos

Filgrastim

Injection 48 million IU/ml Injection 30 million IU/ml Injection 120 micrograms/0.2 mL in pre-filled syringe. Injection 300 micrograms/0.5 mL in pre-filled syringe. Injection 480 micrograms/0.8 mL in pre-filled syringe Injection 480 micrograms/1.6 mL in 1.6 mL vial

Este medicamento esta presente em:

Listas	Seção	Observação
Chile	Essential and Prioritized Medications	Sem observações

Este medicamento esta presente em:

Listas	Seção	Observação
Chile	Essential and Prioritized Medications	Sem observações

Este medicamento esta presente em:

Listas	Seção	Observação
WHO Model List of Essential Medicines (2021)	8.2.3 Immunomodulators	Outras observações: Including quality-assured biosimilars. − Primary prophylaxis in patients at high risk for developing febrile neutropenia associated with myelotoxic chemotherapy. − Secondary prophylaxis for patients who have experienced neutropenia following prior myelotoxic chemotherapy − To facilitate administration of dose dense chemotherapy regimens

Este medicamento esta presente em:

Listas	Seção	Observação
WHO Model List of Essential Medicines (2021)	8.2.3 Immunomodulators	Outras observações: Including quality-assured biosimilars. − Primary prophylaxis in patients at high risk for developing febrile neutropenia associated with myelotoxic chemotherapy. − Secondary prophylaxis for patients who have experienced neutropenia following prior myelotoxic chemotherapy − To facilitate administration of dose dense chemotherapy regimens

Este medicamento esta presente em:

Listas	Seção	Observação
WHO Model List of Essential Medicines (2021)	8.2.3 Immunomodulators	Outras observações: Including quality-assured biosimilars. − Primary prophylaxis in patients at high risk for developing febrile neutropenia associated with myelotoxic chemotherapy. − Secondary prophylaxis for patients who have experienced neutropenia following prior myelotoxic chemotherapy − To facilitate administration of dose dense chemotherapy regimens

Este medicamento esta presente em:

Listas	Seção	Observação
WHO Model List of Essential Medicines (2021)	8.2.3 Immunomodulators	Outras observações: Including quality-assured biosimilars. − Primary prophylaxis in patients at high risk for developing febrile neutropenia associated with myelotoxic chemotherapy. − Secondary prophylaxis for patients who have experienced neutropenia following prior myelotoxic chemotherapy − To facilitate administration of dose dense chemotherapy regimens

Recursos de Informação: Filgrastim

Nenhuma informação disponível